Here’s why CSL Limited (ASX:CSL) and this blue chip ASX share could be blockbuster buys for investors right now…
The post 2 blockbuster blue chip ASX shares to buy in January appeared first on The Motley Fool Australia. –
If you’re planning to add a few blue chip ASX shares to your portfolio in the near future, then I would suggest you consider the two listed below.
As far as these brokers are concerns, they could be among the best on offer on the Australian share market right now. Here’s why they are rated as buys:
CSL Limited (ASX: CSL)
CSL is one of the world’s leading biotherapeutics companies and the name behind the high quality CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies, whereas Seqirus is the second largest influenza vaccines business.
Both of CSL’s businesses have been growing at a solid rate in recent years and have been tipped to continue doing so in the future. This is due to their leading therapies and vaccines, increasing demand, and lucrative research and development pipelines.
In respect to the latter, CSL’s pipeline contains a number of highly promising products that have the potential to generate significant revenues in the future. This includes clazakizumab, which is being developed to treat kidney transplant rejection. This product alone could generate peak sales of US$5.4 billion eventually.
UBS recently retained its buy rating and $346.00 price target on CSL’s shares. This compares to the latest CSL share price of $284.72.
Xero Limited (ASX: XRO)
Another blue chip to look at is Xero. It is one of the world’s leading cloud-based business and accounting software platform providers. Over the last few years the company has successfully evolved from being a place to do your accounts, to a full-service small business solution.
This has helped underpin significant subscriber and revenue growth. For instance, during the first half of FY 2021, Xero finished the period with 2.45 million subscribers. This led to it reporting a 21% increase in operating revenue to NZ$409.8 million and a 15% lift in annualised monthly recurring revenue (AMRR) to NZ$877.6 million.
One broker that is confident there will be more of the same over the 2020s is Goldman Sachs. Last month it initiated coverage on the company with a buy rating and $157.00 price target. Goldman believes Xero can achieve a 2030 subscriber footprint of 7.4 million and generate NZ$3.4 billion in annual revenue.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- 5 things to watch on the ASX 200 on Tuesday
- The top performing ASX 200 tech shares of 2020
- Sonic Healthcare (ASX:SHL) share price gets fresh COVID boost
- Disappointments from the ASX 200’s best ever December quarter
- 2 of the best ASX growth shares to buy in January
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Xero. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post 2 blockbuster blue chip ASX shares to buy in January appeared first on The Motley Fool Australia.